Meta-analysis of TNF-alpha promoter - 238A/G polymorphism and SLE susceptibility. 2010

Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, Anhui, People's Republic of China.

The tumor necrosis factor-alpha (TNF-alpha) promoter--238A/G polymorphism has been repeatedly associated with systemic lupus erythematosus (SLE), but findings are not consistent across studies. Our aim was to do a meta-analysis to assess the association between TNF-alpha promoter--238A/G polymorphism and SLE. Eleven published studies of this polymorphism with SLE in different ethnic groups were identified using a Medline search. Meta-analysis was performed for genotypes AA versus GG, GA versus GG, AA versus GG+GA, GA+AA versus GG, and A allele versus G allele in a fixed/random effect model. The overall odds ratio (OR) of the AA versus GG+GA genotypes was 3.46 (95% CI = 1.35-8.83, P = 0.01), and a similar result was found in Caucasian population (OR = 4.62, 95% CI = 1.20-17.80, P = 0.03); the overall OR of the AA versus GG genotypes was 3.36 (95% CI = 1.32-8.55, P = 0.01), and a similar result was found in Caucasian population (OR = 4.29, 95% CI = 1.11-16.53, P = 0.03); the OR of the GA versus GG genotypes was 0.48 (95% CI = 0.30-0.75, P = 0.001) in Caucasian population. In conclusion, this meta-analysis demonstrates the association between TNF-alpha promoter - 238A/G polymorphism and SLE, especially in Caucasian population.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D044465 White People Persons having origins in any of the white racial groups of Europe, the Middle East, or North Africa. Note that OMB category WHITE is available for the United States population groups. Race and ethnicity terms, as used in the federal government, are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. European Continental Ancestry Group,White Person,Caucasian Race,Caucasoid Race,Caucasian Races,Caucasoid Races,People, White,Person, White,Race, Caucasian,Race, Caucasoid,White Peoples,White Persons
D020022 Genetic Predisposition to Disease A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. Genetic Predisposition,Genetic Susceptibility,Predisposition, Genetic,Susceptibility, Genetic,Genetic Predispositions,Genetic Susceptibilities,Predispositions, Genetic,Susceptibilities, Genetic

Related Publications

Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
March 2006, European journal of human genetics : EJHG,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
August 2012, Molecular biology reports,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
June 2000, The Journal of investigative dermatology,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
June 2001, The Journal of rheumatology,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
February 2012, Molecular biology reports,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
August 2019, Scientific reports,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
July 2012, Rheumatology international,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
January 2014, PloS one,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
January 2017, Neuropsychiatric disease and treatment,
Yan-Feng Zou, and Xiao-Liang Feng, and Fan-Ming Pan, and Hong Su, and Jin-Hui Tao, and Dong-Qing Ye
January 2015, Therapeutics and clinical risk management,
Copied contents to your clipboard!